Telo Genomics study lined up for the next year with the University of Athens

Announcement

Telo Genomics Corp., a champion in prognostic and diagnostic innovation fueled by advanced telomere analytics, has declared its new efforts for a new multiple myeloma (MM) Minimal Residual Disease (MRD) clinical trial in partnership with the University of Athens. The retrospective study based on this initiative is a main component of Telo’s extension, a epicenter MRD validation program and is engineered to examine the clinical utility of the company’s blood-related TeloView®MRD.

The partnership with the University of Athens will provide access to well-defined and driven clinical blood samples with a reflective presentation of patient outcomes and an estimated three years of follow-up. Including the previous serial Next-Generation Flow (NGF) MRD results.

The study’s intention

The study is planned to evaluate the prognostic value of TeloView®MRD in analysing the patient's risk factor of relapse, and further to compare the same work with NGF. It’s two of the most popularly used MRD evaluation approaches in MM. The group involves the NGF MRD results screened and found in bone marrow and blood, which contributes well to the comprehensive comparative dataset.

About TeloView®MRD

The TeloView®MRD is engineered to identify the diseases at peak sensitivity in blood with a predicted limit of identifying down to 1 in 10ᶺ7. Throughout various disease levels. At the scale of comparison, the NGF can touch 10ᶺ6 sensitivity in a few centers. Under the MRD enumeration, the TeloView®MRD assess the 3D genomic architecture of single MRD cells, which can deliver incremental prognostic insight apart from the cell counting alone.

With this testament, the company continues to modernise its prospective MRD trial along with the Jewish General Hospital and the Cleveland Clinic. Telo is also expected to declare its additional reflective partnered studies in Q1 2026. This study will form a epicenter to the large-scale, robust clinical proven package to contribute to the adoption and illustrate comparative performance v/s developed MRD assays. The study will reach its efficacy and accuracy as the education board has always been a valuable and qualified partner to collaborate with.

Telo’s Co-Founder, Dr Sabine Mai, said, “We are grateful to work with Prof. Efstathios Kastritis and Prof. Meletios A. Dimopoulos from the trustworthy Kapodistrian and National University of Athens. This partnership is expected to significantly bolster and double the power of our mission to help us reintroduce the MRD-structured clinical practice by inviting more interactive, blood-related insights to patients and physicians.”